Microdevice for Evaluating Drug Response in Site in Lung Lesions

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions
Lung TumorLung Cancer
Interventions
COMBINATION_PRODUCT

Microdevice loaded with 19 chemotherapeutic agents

The microdevice containing 19 FDA-approved chemotherapeutic agents will be placed in the suspected tumor tissue at the time of surgical resection. Multiple chemotherapeutic agents will passively diffuse into local, confined regions (several microns) of the surrounding microenvironment. The agents are released at approximately one millionth of a systemic dose. The device(s) will be removed for analysis at the time of resection, which will be performed for clinical indications independent of enrollment in this study.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Oliver Jonas

OTHER

NCT03972228 - Microdevice for Evaluating Drug Response in Site in Lung Lesions | Biotech Hunter | Biotech Hunter